Home Newsfeeds JP Morgan Maintains Overweight on Silvergate Capital, Lowers Price Target to $90

JP Morgan Maintains Overweight on Silvergate Capital, Lowers Price Target to $90

JP Morgan analyst Steven Alexopoulos maintains Silvergate Capital (NYSE:SI) with a Overweight and lowers the price target from $200 to $90.

byBenzinga Newsdesk

July 1, 2022

1 minute read

JP Morgan analyst Steven Alexopoulos maintains Silvergate Capital (NYSE:SI) with a Overweight and lowers the price target from $200 to $90.

Important Biotech Catalysts For September 14, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

September 14, 5:29 PM

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON)…

ADVM

PVH Sees Q3 EPS $2.10-$2.15, Sees Revenue Down 4-5%; Sees FY22 Adj. EPS $8.00

By Bill Haddad

August 30, 4:17 PM

Third Quarter 2022 Guidance Revenue is projected to decrease 5% to 4% as compared to the prior year period (increase 4% to 5% on a constant currency basis), reflecting a 2% reduction resulting from the impact of the Third Quarter 2022 Guidance

PVH

Avadel Pharmaceuticals Announces Final FDA Approval Of LUMRYZ For Extended-Release Oral Suspension As The First And Only Once-At-Bedtime Oxybate For Cataplexy Or Excessive Daytime Sleepiness In Adults With Narcolepsy

By Benzinga Newsdesk

May 1, 1:21 PM

- Granted Orphan Drug Exclusivity through May 1, 2030 --Advanced commercial preparations on track; LUMRYZ product availability expected in early June -- Final approval supported by robust efficacy and safety data from

AVDL

Vitalik Buterin Says War In Ukraine ‘Not The Only Terrible War’ Happening In World Right Now, Pointing To Tigray

By Navdeep Yadav

August 29, 6:04 AM

Ethereum (CRYPTO: ETH) co-founder Vitalik Buterin pointed toward the ongoing civil war in Tigray and said Vladimir Putin's invasion of Ukraine is "not the only terrible war happening right now."

ETH

JP Morgan Maintains Overweight on Silvergate Capital, Lowers Price Target to $90

Related Posts

Important Biotech Catalysts For September 14, 2022 – End Of The Day Summary

PVH Sees Q3 EPS $2.10-$2.15, Sees Revenue Down 4-5%; Sees FY22 Adj. EPS $8.00

Avadel Pharmaceuticals Announces Final FDA Approval Of LUMRYZ For Extended-Release Oral Suspension As The First And Only Once-At-Bedtime Oxybate For Cataplexy Or Excessive Daytime Sleepiness In Adults With Narcolepsy

Vitalik Buterin Says War In Ukraine ‘Not The Only Terrible War’ Happening In World Right Now, Pointing To Tigray